Beilu Pharma(SZ:300016) Zhong Guo Jing Ji Wang·2025-07-03 03:20Core Viewpoint - Northern Pharmaceutical (300016.SZ) announced a share transfer plan where major shareholder Wang Daixue intends to transfer 7,378,344 shares, representing 1.49% of the total share capital as of July 1, 2025, due to personal funding needs [1][2]. Company Summary - Wang Daixue holds 7,378,344 shares, accounting for 1.49% of the total share capital, and is the controlling shareholder with over 5% ownership [1][2]. - The share transfer will be conducted through a non-public inquiry method, and the transferee will be institutional investors with appropriate pricing and risk-bearing capabilities [1][2]. - The transferred shares cannot be sold by the transferee within six months after the transfer [1]. Financial Performance Summary - Revenue for the years 2022 to 2024 was reported as follows: 766.0 million yuan in 2022, 891.0 million yuan in 2023, and 984.0 million yuan in 2024, reflecting a growth of 10.42% year-over-year [2][3]. - Net profit attributable to shareholders showed fluctuations: 11.3 million yuan in 2022, a loss of 71.8 million yuan in 2023, and a profit of 13.7 million yuan in 2024, indicating a significant recovery with a 119.02% increase from the previous year [2][3]. - The net profit after excluding non-recurring items also improved from a loss of 26.6 million yuan in 2022 to a profit of 14.1 million yuan in 2024, marking a 120.27% increase [2][3]. - The net cash flow from operating activities was reported as 127.8 million yuan in 2022, 58.5 million yuan in 2023, and 163.0 million yuan in 2024, showing a substantial increase of 178.85% year-over-year [2][3].